enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Neurocrine Biosciences Reports Mixed Q4 - AOL

    www.aol.com/finance/neurocrine-biosciences...

    After all, Stock Advisor’s total average return is 929% — a market-crushing outperformance compared to 177% for the S&P 500.* They just revealed what they believe are the 10 best stocks for ...

  3. Loss-Making Neurocrine Biosciences Inc (NASDAQ:NBIX ... - AOL

    www.aol.com/loss-making-neurocrine-biosciences...

    Neurocrine Biosciences Inc’s (NASDAQ:NBIX): Neurocrine Biosciences, Inc. discovers and develops pharmaceuticals for the treatment of neurological and endocrine-related diseases and disorders in ...

  4. Why Is Neurocrine Biosciences Stock Trading Lower On Friday? On Thursday, Neurocrine Biosciences Inc. (NASDAQ:NBIX) reported fourth-quarter adjusted EPS of $1.69, higher than the $1.54 reported a ...

  5. Neurocrine Biosciences - Wikipedia

    en.wikipedia.org/wiki/Neurocrine_Biosciences

    Neurocrine received upfront fees and early milestone payments totaling $25.5 million. [13] In December 2002, Neurocrine reached an agreement with Pfizer for the rights to its experimental insomnia drug, indiplon. [14] [15] The deal paid Neurocrine $100 million initially with a possible $300 million more if the drug met regulatory and sales ...

  6. Notable Neurocrine Biosciences Insider Trades $1.1M In ... - AOL

    www.aol.com/news/notable-neurocrine-biosciences...

    They then sold their shares on the same day in the open market. They sold at pr ... Dimitri Grigoriadis exercised options to purchase 5,000 Neurocrine Biosciences shares at a price of $43.24 per ...

  7. Neurocrine Biosciences (NBIX) Reports Q4 Loss, Misses ... - AOL

    www.aol.com/news/neurocrine-biosciences-nbix...

    Neurocrine (NBIX) delivered earnings and revenue surprises of -113.11% and 1.22%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

  8. Neurocrine Biosciences Shares Rise Despite Disappointing Q4 ...

    www.aol.com/news/neurocrine-biosciences-shares...

    For premium support please call: 800-290-4726 more ways to reach us

  9. Was The Smart Money Wrong About Neurocrine Biosciences, Inc ...

    www.aol.com/news/smart-money-wrong-neurocrine...

    Many prominent investors, including Warren Buffett, David Tepper and Stan Druckenmiller, have been cautious regarding the current bull market and missed out as the stock market reached another ...